Filing Flows

Filing Flows › Companies › Biolargo › Cash flow

Biolargo cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$3.1M in Q2 2026 · −$10.3M over twelve months

Operating cash flow−$3.1M
Free cash flow−$3.1M
Cash conversion cycle-36 days

Analysis

In Q2 2026, Biolargo generated −$3.1M of operating cash flow. That is $938K less than in Q2 2025 (−$2.1M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$10.3M; the largest uses were operating cash flow ($10.3M); besides operations, cash came from other financing ($7.1M), shares issued ($1.9M); the cash balance fell by $1.3M.

Operating cash flow was −$3.1M against net income of −$4.0M. The largest differences: stock-based pay +$722K, deferred revenue −$273K, depreciation & amortization +$31K.

Its cash conversion cycle was -36 days (receivables 53 + inventory 47 − payables 136): suppliers fund its working capital.

Free cash flow

Biolargo: free cash flow by quarterBiolargo: free cash flow by quarter−$1.6MQ3 2024−$1.9MQ4 2024−$1.8MQ1 2025−$2.1MQ2 2025−$2.8MQ3 2025−$1.6MQ4 2025−$2.9MQ1 2026−$3.1MQ2 2026
Operating cash flow less capital spending.
Biolargo: operating cash flow against capital spendingBiolargo: operating cash flow against capital spendingOperating cash flowCapital spending−$1.6M$0Q3 2024−$1.9M$0Q4 2024−$1.8M$0Q1 2025−$2.1M$0Q2 2025−$2.8M$0Q3 2025−$1.6M$0Q4 2025−$2.9M$0Q1 2026−$3.1M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$3.1M, Capital spending $0.

Capital allocation, year by year

Biolargo: where the cash came from (up) and went (down), by fiscal yearBiolargo: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedFY2021: Operating cash flow −$3.9MFY2021: Net borrowing −$865KFY2021: Shares issued $4.9M$4.9MFY2021FY2022: Operating cash flow −$2.8MFY2022: Net borrowing $48KFY2022: Shares issued $3.9M$3.9MFY2022FY2023: Operating cash flow −$2.4MFY2023: Net borrowing $38KFY2023: Shares issued $3.7M$3.8MFY2023FY2024: Operating cash flow −$3.2MFY2024: Net borrowing −$14KFY2024: Shares issued $747K$747KFY2024FY2025: Operating cash flow −$8.3MFY2025: Net borrowing $24KFY2025: Shares issued $2.0M$2.1MFY2025
Over these 5 years operating cash flow totalled −$20.6M; the largest uses were operating cash flow ($20.6M) and net borrowing ($879K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$2.2M
Debt$2.1M
Net cash$109K
Due within a year$83K
Cash runway3 months

Biolargo is burning cash: its operations consume cash, a free cash flow of −$10.3M a year at the current rate against $2.2M of cash and investments: a runway of about 3 months; $83K of debt also comes due within a year, which would need refinancing or new money before any new financing.

Where the cash came from and went

Biolargo: sources (+) and uses (−) of cash, Q2 2026Biolargo: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$3.1MCash drawn (+) / kept (−)$1.9MNet borrowing (+) / repaid (−)$1.0MShares issued$391KOther investing−$160KOther financing−$112KExchange rates$3K
Biolargo: sources (+) and uses (−) of cash, TTM to Q2 2026Biolargo: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$10.3MOther financing$7.1MShares issued$1.9MCash drawn (+) / kept (−)$1.3MOther investing$51KNet borrowing (+) / repaid (−)$17KExchange rates−$3K

From profit to cash

Biolargo: net income to operating cash flow, Q2 2026Biolargo: net income to operating cash flow, Q2 2026Net income−$4.0MDepreciation & amortization$31KStock-based pay$722KReceivables−$7KInventory−$11KDeferred revenue−$273KPrepaid and other assets$14KOperating cash flow−$3.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20265347136-36
Q1 20265441127-31
Q4 2025103681691
Q3 20251045412434
Q2 202597277846
Q1 2025102185069
Q4 202480145836
Q3 20245675310

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$3.1M$1.0M$391K$1.9M−$3.1M
Q1 2026−$2.9M$2.4M$256K−$239K−$2.9M
Q4 2025−$1.6M——$663K−$1.6M
Q3 2025−$2.8M−$9K—−$1.1M−$2.8M
Q2 2025−$2.1M$666K$808K−$907K−$2.1M
Q1 2025−$1.8M$586K−$15K$984K−$1.8M
Q4 2024−$1.9M—$245K$334K−$1.9M
Q3 2024−$1.6M−$4K−$207K$883K−$1.6M

Biolargo: income statement and cash flow

Biolargo, Q2 2026: revenue $1.2M (-55% year over year), operating margin -298.7%. The chart follows the revenue to costs, profit and cash.

Biolargo: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.